Dual‑Checkpoint Melanoma Therapy and KRAS‑Targeted Pancreatic Drug Show Promising Trial Results

A phase III trial of a novel dual‑checkpoint immunotherapy for high‑risk melanoma reported a 42% reduction in disease progression and a 67% progression‑free survival rate at 18 months, prompting the European Medicines Agency to begin a rolling review and the U.S. FDA to grant priority review status.

In a separate phase III study, the KRAS‑inhibitor daraxonrasib doubled overall survival for patients with advanced pancreatic cancer, a disease with a five‑year survival rate of only 13‑14%. The trial, presented at the 2026 ASCO meeting, may lead to FDA approval and become the new first‑line standard of care, potentially extending to other RAS‑driven cancers.

Both trials involve multinational cohorts and could reshape treatment protocols for melanoma and pancreatic cancer, offering new targeted options beyond existing chemotherapy and checkpoint inhibitors.